Literature DB >> 2434742

Influence of protein binding on the myocardial uptake and pharmacodynamics of propafenone.

A M Gillis, R E Kates.   

Abstract

The relationship between plasma protein binding, myocardial uptake, and cardiac pharmacodynamics of propafenone was studied in an isolated perfused rabbit heart model. Hearts were perfused with buffer which contained varied concentrations of alpha 1-acid glycoprotein (alpha 1AGP). The rate and extent of myocardial uptake was assessed, as was the time course and magnitude of the change in QRS duration. The addition of alpha 1AGP has significant influence on both the rate and extent of myocardial accumulation as well as the resultant changes in QRS duration. The steady-state changes in QRS duration were linearly related to the free perfusate propafenone concentration. At times of disequilibrium, the relationship between free concentration and effect was not evident. However, at all times, a linear relationship between the myocardial concentration of propafenone and the resultant effect was observed. This relationship was not influenced by addition of alpha 1AGP protein to the perfusate; however, the amount of drug which was able to partition into the myocardium was greatly affected. These studies demonstrate that protein binding does influence the partitioning of drug into the myocardium and subsequently modulates the cardiac effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2434742     DOI: 10.1097/00005344-198611000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Effects of propafenone on K currents in human atrial myocytes.

Authors:  A Seki; N Hagiwara; H Kasanuki
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

2.  Effect of plasma protein binding on kinetics of capillary uptake and efflux.

Authors:  D J Morgan; J L Huang
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 3.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 5.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.